

# Radionuclide therapy



**AC Hotel Palau de Bellavista**

**24-25 May, 2019**

**Gerona, Spain**

Organizing and Scientific Committee:

Prof. Alex Maes, Prof. Laurence Beels, Dr. Filippo Galli,  
Prof. Olivier Gheysens, Prof. Felix Mottaghy, Prof. Mike Sathekge,  
Prof. Christophe Van de Wiele

Preliminary Programme



Friday 24<sup>th</sup> of May 2019

**RADIONUCLIDE TREATMENT OF METASTATIC CASTRATION RESISTANT PROSTATE CARCINOMA AND THYROID CARCINOMA**

*Moderators: Alex Maes, Olivier Gheysens*

8h00-8h30	<b>Radiumchloride (Xofigo) for the treatment of bone metastases in cRMPC</b> Karolien Goffin, Leuven, Belgium
8h30-9h00	<b>Proper indications for 177Lu/225Ac-PSMA radioligand therapy of cRMPC: German guidelines</b> Felix Mottaghy, Aachen, Germany
9h00-9h30	<b>Dosimetric aspects of 177Lu- and 225Ac-based radionuclide therapy</b> Klaus Bacher, Ghent, Belgium
9h30-10h00	<b>177Lu-PSMA therapy: clinical results using the PSMA I&amp;T kit</b> Richard Baum, Bad Berka, Germany

10h00-10h30 Coffee break

*Moderators: Alex Maes, Olivier Gheysens*

10h30-11h00	<b>177Lu-PSMA therapy: clinical results using the PSMA167 kit</b> Hojjat Ahmadzadehfar, Bonn, Germany
11h00-11h30	<b>225Ac-PSMA therapy: clinical results</b> Mike Sathekge, Pretoria, South-Africa
11h30-12h00	<b>Radioiodine ablation in patients with low-risk thyroid carcinoma</b> Ujjal Mallick, Newcastle upon Tyne, UK
12h00-12h30	<b>Genetics in thyroid carcinoma: effect on RAI therapy outcome</b> Alberto Signore, Rome, Italy
12h30-13h00	<b>Peptide receptor radionuclide therapy of radioiodine treatment refractory or non radioiodine avid metastatic thyroid cancer using 90Y and 177Lu-labelled somatostatin analogs: toxicity, response and survival analysis.</b> Richard Baum, Bad Berka, Germany
13h00-14h00	<b>Discussion</b>

14h00-15h00 Lunch Break

15h00-16h00 Meet the expert: Radionuclide prostate and thyroid therapy

16h00-17h00 Clinical cases: Radionuclide prostate and thyroid therapy

20h00-23h00 Social dinner

## Saturday 25<sup>th</sup> of May 2019

### **RADIONUCLIDE TREATMENT OF LIVER MALIGNANCIES AND NEUROENDOCRINE MALIGNANCIES**

*Moderators: Laurence Beels, Etienne Garin*

8h00-8h30	<b>Radiological aspects of SIRT</b> Geert Maleux, Leuven, Belgium
8h30-9h00	<b>Dosimetric aspects of SIRT</b> Klaus Bacher, Ghent, Belgium
9h00-9h30	<b>90Y-labelled microspheres for treatment of liver metastases: clinical results</b> Philip Hilgard, Essen, Germany
9h30-10h00	<b>90Y-labelled microspheres for treatment of HCC: clinical results</b> Etienne Garin, Rennes, France

10h00-10h30 Coffee break

*Moderators: Klaus Bacher, John Buscombe*

10h30-11h00	<b>SIRT using 166Holmium microspheres: clinical results</b> Marnik Lam, Utrecht, The Netherlands
11h00-11h30	<b>Clinical indications for Peptide Receptor Radionuclide Therapy (PRRT)</b> Speaker to be confirmed
11h30-12h00	<b>PRRT: clinical results.</b> John Buscombe, Cambridge, UK
12h00-12h30	<b>PRRT: dosimetric and radiobiological considerations</b> Martha Cremonesi, Milano, Italy
12h30-13h00	<b>Prediction of response to PRRT</b> Lisa Bodei, New York, USA
13h00-14h00	<b>Discussion</b>

14h00-15h00 Lunch Break

15h00-16h00 Meet the expert: SIRT and PRRT

16h00-17h00 Clinical cases: SIRT and PRRT



**REGISTRATION:** [www.azgroeninge.be/radionuclide](http://www.azgroeninge.be/radionuclide)